This study aimed to identify the economic burden of inflammatory bowel disease (IBD) by comparing mean annual IBD-related medical costs and events (e.g., inpatient hospitalizations, emergency department visits, and outpatient visits) for MassHealth members before and after ustekinumab initiation. Initiation of treatment with ustekinumab was not associated with statistically significant changes in mean annual IBD-related medical costs or events in the overall study population; however, increased medical costs were observed among patients in a high- dose cohort.
Changes in Healthcare Resource Utilization Following Initiation of Ustekinumab in Members with Inflammatory Bowel Disease in a Medicaid Population
Commonwealth Medicine is now ForHealth Consulting at UMass Chan Medical School. More information available here. This content has not been updated with the new name.